Friday, December 05, 2025 | 04:12 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Pfizer's Covid vaccine candidate prevents 90% of infections in large study

The findings are based on an interim analysis conducted after 94 participants contracted Covid-19

Coronavirus, vaccine, covid
premium

The trial’s data monitoring committee has identified no serious safety concerns, according to Pfizer and BioNTech

Robert Langreth, Naomi Kresge and Riley Griffin | Bloomberg
The Covid-19 vaccine being developed by Pfizer Inc. and BioNTech SE prevented more than 90% of infections in a study of tens of thousands of volunteers, the most encouraging scientific advance so far in the battle against the coronavirus.

Eight months into the worst pandemic in a century, the preliminary results pave the way for the companies to seek an emergency-use authorization from regulators if further research shows the shot is also safe.

The findings are based on an interim analysis conducted after 94 participants contracted Covid-19. The trial will continue until 164 cases have occurred. If the data hold